Polish Journal of Paediatrics
en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2026
vol. 101
 
Share:
Send email
Share:
Original paper

Analysis of selected biomarkers of obesity-related complications in the paediatric population

Oliwia Piaskowska
1
,
Anna Jakubowska
2
,
Agnieszka Matera-Witkiewicz
3
,
Mateusz Sikora
3
,
Magdalena Krupińska
3
,
Agnieszka Bargenda-Lange
1
,
Anna Medyńska
1
,
Katarzyna Zatońska
4
,
Katarzyna Połtyn-Zaradna
4
,
Tomasz Zatoński
5
,
Katarzyna Kiliś-Pstrusińska
1

  1. Faculty of Pharmacy, Wroclaw Medical University, Wroclaw, Poland
  2. Clinical Department of Paediatric Nephrology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland
  3. Screening of Biological Activity Assays and Collection of Biological Material Laboratory, Faculty of Pharmacy, Wroclaw Medical University, Wroclaw Medical University Biobank, Wroclaw, Poland
  4. Department of Population Research and Prevention of Lifestyle Diseases, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland
  5. Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland
Pediatr Pol 2026; 101 (1): 36-42
DOI: https://doi.org/10.5114/polp.2026.160530
Online publish date: 2026/03/27
Article file
- Analysis of selected - Piaskowska.pdf  [0.20 MB]
Get citation
 
PlumX metrics:
 
1. World Health Organization Regional Office for Europe. WHO European Regional Obesity Report 2022. Copenhagen: WHO Regional Office for Europe; 2022. Licence: CC BY-NC-SA 3.0 IGO.
2. Pawlewicz A. Otyłość i jej konsekwencje. National Health Fund, Department of Analysis, Quality Monitoring and Services Optimization, Warsaw 2024.
3. Mazur A, Zachurzok A, Baran J, Dereń K, Łuszczki E, Weres A, et al. Otyłość dziecięca. Stanowisko Polskiego Towarzystwa Pediatrycznego, Polskiego Towarzystwa Otyłości Dziecięcej, Polskiego Towarzystwa Endokrynologii i Diabetologii Dziecięcej, Kolegium Lekarzy Rodzinnych w Polsce oraz Polskiego Towarzystwa Badań nad Otyłością. Med Prakt Pediatr 2023; 1: 5-43.
4. Yim H, Yoo K. Obesity and chronic kidney disease: prevalence, mechanism, and management. Clin Exp Pediatr 2021; 64: 511-518.
5. Kułaga Z, Różdżyńska A, Palczewska I, Napieralska E, Litwin M, Różdżyńska-Świątkowska A, et al. Siatki centylowe wysokości, masy ciała i wskaźnika masy ciała dzieci i młodzieży w Polsce – wyniki badania OLAF. Stand Med Pediatr 2010; 7: 690-700.
6. Medyńska A, Chrzanowska JM, Kościelska-Kasprzak K, Bartoszek D, Żabińska M, Zwolińska D. Alpha-1 acid glycoprotein and podocin mRNA as novel biomarkers for early glomerular injury in obese children. J Clin Med 2021; 10: 4129.
7. Zatońska K, Basiak-Rasała A, Matera-Witkiewicz A. Population Cohort Study of Wroclaw Citizens (PICTURE) – study protocol. J Health Inequal 2022; 8: 37-43.
8. Matera-Witkiewicz A, Gleńska-Olender J, Zagórska K, Uhrynowska-Tyszkiewicz I, Witoń M. Standardy jakości dla biobanków polskich v. 2.00. Uniwersytet Medyczny im. Piastów Śląskich, Wrocław 2021, 50.
9. Smirnov NV. Table for estimating the goodness of fit of empirical distributions. Ann Math Statist 1948; 19: 279-281.
10. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist 1947; 18: 50-60.
11. Brzeziński M, Metelska P, Myśliwiec M, Szlagatys-Sidorkiewicz A. Lipid disorders in children living with overweight and obesity – large cohort study from Poland. Lipids Health Dis 2020; 19: 47.
12. Hui N, Barter P, Ong K, Rye KA. Altered HDL metabolism in meta­bolic disorders: insights into the therapeutic potential of HDL. Clin Sci 2019; 133: 2221-2235.
13. McPhee PG, Singh S, Morrison KM. Childhood obesity and cardiovascular disease risk: working toward solutions. Can J Cardiol 2020; 36: 1352-1361.
14. Cho K. Biomedicinal implications of high-density lipoprotein: its composition, structure, functions, and clinical applications. BMB Rep 2009; 42: 393-400.
15. Cho K. The current status of research on high-density lipoproteins (HDL): a paradigm shift from HDL quantity to HDL quality and HDL functionality. Int J Mol Sci 2022; 23: 3967.
16. Kavey REW. Combined dyslipidemia in childhood. J Clin Lipidol 2015; 9: 41-S56.
17. Nur Zati Iwani AK, Jalaludin MY, Roslan FA, MansorF, Zain F, Hua Hong JY, et al. Cardiometabolic risk factors among children who are affected by overweight, obesity and severe obesity. Front Public Health 2023; 11: 1097675.
18. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci 2021; 22: 9221.
19. Li M, Hou W, Zhang X, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis 2014; 232: 265-270.
20. Dutta A, Henley W, Pilling L, Wallace RB, Melzer D. Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc 2013; 61: 319-326.
21. Li M, Hu X, Fan Y, Li K, Zhang X, Hou W, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality: a systematic review and dose-response meta-analysis. Sci Rep 2016; 6: 19520.
22. Jiang Z, Zhao M, Voilquin L, Jung Y, Aikio MA, Sahai T, et al. Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis. Cell Metab 2021; 33: 1836-1852.e11.
23. Gao G, Zhou Z. Isthmin-1: a critical regulator of branching morphogenesis and metanephric mesenchyme condensation during early kidney development. BioEssays 2023; 45: e2300189.
24. Xu M, Feng R, Feng R, Yin X, Zhang L, Wang C, et al. Glomerular filtration rate in patients with type 2 diabetes mellitus: is serum isthmin-1 level a possible link? BMJ Open Diabetes Res Care 2023; 11: e003402.
25. Alshawaf E, Marafie SK, Abu-Farha M, Albatineh AN, Alramah T, Albuhairi A, et al. Circulating Isthmin-1 levels and their relationship with diabetes and metabolic diseases in Kuwaiti adults. Biomedicines 2025; 13: 101.
26. Ruiz-Ojeda FJ, Anguita-Ruiz A, Rico MC, Leis R, Bueno G, Moreno LA, et al. Serum levels of the novel adipokine isthmin-1 are associated with obesity in pubertal boys. World J Pediatr 2022; 19: 864-872.
27. Jiang Z, Zhao M, Voilquin L, Jung Y, Aikio MA, Sahai T, et al. Isthmin-1 is an adipokine that promotes glucose uptake and improves glucose tolerance and hepatic steatosis. Cell Metab 2021; 33: 1836-1852.e11.
28. Kostapanos M, Derdemezis C, Filippatos T, Milionis HJ, Kiortsis DN, Tselepis AD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 578: 249-252.
29. Kaminska A, Kopczynska E, Bronisz A, Żmudzińska M, Bieliński M, Borkowska A, et al. An evaluation of visfatin levels in obese subjects. Endokrynol Pol 2010; 61: 169-173.
30. Zahorska‐Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocełak P, Semik-Grabarczyk E, Holecki M, et al. Serum concentration of visfatin in obese women. Metabolism 2007; 56: 1131-1134.
31. Chang YH, Chang DM, Lin K, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic review. Diabetes Metab Res Rev 2011; 27: 515-527.
32. Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008; 79: 412-418.
33. Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr 2007; 85: 399-404.
34. Lee KJ, Shin YA, Lee KY, Jun TW, Song W. Aerobic exercise training-induced decrease in plasma visfatin and insulin resistance in obese female adolescents. Int J Sport Nutr Exerc Metab 2010; 20: 275-281.
35. Santilli F, Liani R, Di Fulvio P, Formoso G, Simeone P, Tripaldi R, et al. Increased circulating resistin is associated with insulin resistance, oxidative stress and platelet activation in type 2 diabetes mellitus. Thromb Haemost 2016; 116: 1089-1099.
36. Romejko K, Rymarz A, Szamotulska K, Bartoszewicz Z, Rozmyslowicz T, Niemczyk S. Resistin contribution to cardiovascular risk in chronic kidney disease male patients. Cells 2023; 12: 999.
37. Tripathi D, Kant S, Pandey S, Ehtesham NZ. Resistin in metabolism, inflammation and disease. FEBS J 2020; 287: 1815-1827.
38. Koch V. Obesity facts and their influence on renal function across the life span. Front Med 2021; 8: 704409.
Copyright: © 2026 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.